Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar barpenne (< 20) Submitted: 7/10/2012 12:19:06 AM : Outperform Start Price: $9.26 HALO Score: -41.41

Good things on th ehorizon for Halozyme

Member Avatar zzlangerhans (99.78) Submitted: 8/1/2012 11:22:18 PM
Recs: 0

Turns out that was an ICBM you saw on the horizon.

Featured Broker Partners


Advertisement